Significant improvement in radiographic progression-free survival seen first in BRCA subgroup. HealthDay News — For patients with metastatic castration-sensitive prostate cancer (mCSPC) with ...
A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay disease progression in men with specific DNA repair gene mutations. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results